Cargando…
Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis
BACKGROUND: Dupilumab is a monoclonal antibody against interleukin 4 receptor alpha and has proven to be clinically effective in treating patients with chronic rhinosinusitis with nasal polyps (CRSwNP). However, a certain number of patients are non- or partial responders. This study aims to investig...
Autores principales: | Brkic, Faris F., Liu, David T., Rücklinger, Iris, Campion, Nicholas James, Bartosik, Tina Josefin, Vyskocil, Erich, Stanek, Victoria, Tu, Aldine, Gangl, Katharina, Schneider, Sven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676571/ https://www.ncbi.nlm.nih.gov/pubmed/38007429 http://dx.doi.org/10.1186/s40463-023-00660-7 |
Ejemplares similares
-
Dupilumab‐induced skin‐associated side effects in patients with chronic rhinosinusitis with nasal polyposis
por: Chromy, David, et al.
Publicado: (2022) -
The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP
por: Campion, Nicholas J., et al.
Publicado: (2023) -
Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease
por: Schneider, Sven, et al.
Publicado: (2023) -
The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids
por: Bartosik, Tina J., et al.
Publicado: (2023) -
Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
por: Bertlich, Mattis, et al.
Publicado: (2022)